HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
Genzyme
Genzyme Corp.One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since its founding in 1981, the company has introduced breakthrough treatments that have provided new hope for patients. The company’s areas of focus are rare genetic diseases, multiple sclerosis, cardiovascular disease, and endocrinology. Genzyme is a Sanofi company.

Genzyme's press releases and other company information are available at www.genzyme.com.

Genzyme RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations 3013
2 Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro®) 4843
3 Mipomersen Data Presented at European Atherosclerosis Society Congress 5446
4 Genzyme Reports Financial Results for the Third Quarter of 2010 8257
5 Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC 8615
6 Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen 8349
7 Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population 8425
8 European Commission Approves Genzyme's Mozobil 8844
9 Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease 9231
10 Genzyme Receives Positive Opinion for European Approval of Mozobil 8291
11 Genzyme Reports Solid Financial Results for the First Quarter of 2009 8293
12 European Authorities Approve Larger-Scale Production of Genzyme's Myozyme 6034
13 Strong Fourth Quarter for Genzyme Concludes Productive Year 5280
14 Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth 3093
 
Bookmark and Share